Clinical Trial

The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized controlled crossover trial aimed to evaluate the efficacy and safety of dapagliflozin in the treatment of hereditary kidney disease with proteinuria in children
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-17; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2025-06-12
Trial Details
NCT Number NCT06890143
Lead Sponsor Children's Hospital of Fudan University
Collaborators: Guangzhou Women and Children's Medical Center, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Shandong Provincial Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Wuhan Children's Hospital, Xuzhou Children Hospital, First Affiliated Hospital, Sun Yat-Sen University, Kunming Children's Hospital, The Children's Hospital of Zhejiang University School of Medicine, Children's Hospital of Nanjing Medical University, Zhengzhou Children's Hospital, China, Xiamen Women's and Children's Hospital, Guiyang Maternity and Child Health Care Hospital, Maternal and Child Health Care Hospital of Hainan Province, Children's Hospital of The Capital Institute of Pediatrics, Second Affiliated Hospital of Wenzhou Medical University, Xian Children's Hospital, The Second Hospital of Hebei Medical University, Wuxi Women's & Children's Hospital, First People's Hospital of Urumqi
Conditions Pediatric Hereditary Kidney Diseases
Enrollment 44 participants
Start Date 2025-03-22
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-06